• Radiation Therapy
      • Treatment Delivery
        • Unity Unity
        • Versa HD Versa HD
        • Harmony Harmony
        • Elekta Infinity Elekta Infinity
        • Elekta Synergy Elekta Synergy
      • Treatment Management
        • Monaco
        • ProKnow
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Leksell Gamma Knife Icon Leksell Gamma Knife Icon
        • Leksell Gamma Knife Perfexion Leksell Gamma Knife Perfexion
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell Gamma Knife Lightning
        • Leksell GammaPlan
    • Oncology Informatics
      • MOSAIQ Plaza
        • Subscribe to better
        • Professional Services
        • Interoperability
      • Elekta Axis Cloud
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Rectum
        • Bladder
        • Gynecology
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
        • Leksell Stereotactic System Leksell Stereotactic System
    • Veterinary Radiation Therapy
    • Elekta Care Customer Services
    • Elekta Care Learning
    • Elekta Care Community
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Management
        • Integrity Line
        • Programs
        • Sponsorship and Donation
        • Story
    • Sustainability
      • Sustainability
        • Access to healthcare
        • Business Ethics
        • Global Environment Policy
        • Green Processes
        • People and Human Rights Policy
        • People in Focus
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Management
              • Auditors
              • Articles of Association
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • The share
                  • Financials
                    • Funding
                      • Reports & presentations
                      • Press releases
                      • IR calendar
                      • IR contacts
                  • Newsroom
                    • Newsroom
                      • Press Releases
                      • FOCUS magazine
                      • Events
                      • Image bank
                  • Careers at Elekta
                  • Company Update
                  • Reimbursement Support & Policy
                ENSV
                Login
                • Products
                  • Radiation Therapy
                    • Treatment Delivery
                      • Unity
                      • Versa HD
                      • Harmony
                      • Elekta Infinity
                      • Elekta Synergy
                    • Treatment Management
                      • Monaco
                      • ProKnow
                    • Quality Assurance
                      • Machine QA
                      • Patient QA
                  • Stereotactic Radiosurgery
                    • Delivery
                      • Leksell Gamma Knife Icon
                      • Leksell Gamma Knife Perfexion
                    • Treatment Planning
                      • Leksell Gamma Knife Lightning
                      • Leksell GammaPlan
                    • Versa HD
                  • Oncology Informatics
                    • MOSAIQ Plaza
                      • Subscribe to better
                      • Professional Services
                      • Interoperability
                    • Elekta Axis Cloud
                  • Brachytherapy
                    • Elekta Studio
                    • ImagingRing
                    • Venezia
                    • Flexitron
                    • Geneva
                    • Head and Neck
                    • Bronchus and Oesophagus
                    • Breast
                    • Skin
                    • Prostate
                    • Rectum
                    • Bladder
                    • Gynecology
                    • Oncentra Brachy
                  • Neurosurgery
                    • Leksell Vantage Stereotactic System
                    • Leksell Stereotactic System
                  • Veterinary Radiation Therapy
                • Services
                  • Elekta Care Customer Services
                  • Elekta Care Learning
                  • Elekta Care Community
                • Patients
                  • Brachytherapy Treatment
                  • Gamma Knife Treatment
                  • Radiation Therapy Treatment
                  • Treatment Centers
                • Company
                  • About us
                    • Board of Directors
                    • Code of Conduct
                    • Corporate Citizenship
                    • Executive Management
                    • Integrity Line
                    • Programs
                    • Sponsorship and Donation
                    • Story
                  • Sustainability
                    • Access to healthcare
                    • Business Ethics
                    • Global Environment Policy
                    • Green Processes
                    • People and Human Rights Policy
                    • People in Focus
                  • Corporate Governance
                    • Shareholders’ meetings
                      • Board of Directors
                        • Executive Management
                          • Auditors
                          • Articles of Association
                          • Reports
                        • Investors
                          • Investment case
                            • Outlook
                            • The share
                              • Financials
                                • Funding
                                  • Reports & presentations
                                  • Press releases
                                  • IR calendar
                                  • IR contacts
                                • Newsroom
                                  • Press Releases
                                  • FOCUS magazine
                                  • Events
                                  • Image bank
                                • Careers at Elekta
                                • Company Update
                                • Reimbursement Support & Policy
                              • Contact
                              • Medical Affairs
                              • Regulatory Affairs
                              • Suppliers
                                • About Elekta Procurement
                                • Sustainable Sourcing
                                • Performance Management
                                  • Production Part Approval Process
                                  • Supplier Escalation Form
                                  • Non Conformance Management
                                  • Supplier Performance Management
                                  • Obsolescence Management
                                • Compliance Management
                                • Invoicing Process
                                • Elekta T&C
                                • Documents & Training
                                • Our Global Presence
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube

                              New data presented at ESTRO 35 show positive cosmesis and favorable late side effects after Accelerated Partial Breast Irradiation (APBI) with multicatheter interstitial brachytherapy

                              May 02, 2016
                              Phase III trial further reinforces treatment as a valid alternative to whole breast irradiation in patients with early breast cancer

                              Clinical equivalence of partial breast irradiation (PBI) and whole breast irradiation (WBI) has been demonstrated in two key phase III randomized trials: the Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) trial administering PBI in five days with multicatheter interstitial brachytherapy (published in the Lancet), and  the IMPORT-Low trial administering PBI in three weeks with IMRT (presented at the 10th European Breast Cancer Conference).

                              Today, additional results from the GEC-ESTRO trial (abstract #OC-0481), a multicenter phase III study comparing APBI with interstitial multicatheter brachytherapy to WBI were presented by Prof. Csaba Polgár MD, PhD, MSc, Professor and Head of the Radiotherapy Center at the National Institute of Oncology in Budapest, Hungary and co-lead study author, at ESTRO 35 in a session from 12 – 12:45 p.m.

                              The primary objective of the GEC-ESTRO trial was to assess the role of APBI brachytherapy alone compared to WBI with boost in a defined group of patients with invasive (stage I-IIA) breast cancer or ductal carcinoma in situ (DCIS; stage 0) who underwent breast-conserving surgery. Researchers evaluated a total of 1,184 patients aged 40 years and above who were randomized to a standardized treatment arm (WBI, n=551) or an investigational treatment arm (APBI, n=633). The median follow up in the study was 6.6 years.

                              “My colleagues and I are pleased to share the data from the GEC-ESTRO trial which further validate the established and growing body of clinical evidence supporting APBI with multicatheter interstitial brachytherapy as a safe and effective alternative to WBI,” says Prof. Polgár. “The convenience of this five-day treatment coupled with excellent cosmetic outcomes make this a very attractive treatment option for women with early breast cancer.”

                              Previous findings from the multicenter study conducted by GEC-ESTRO, already published in the Lancet, demonstrate that APBI with multicatheter interstitial brachytherapy has an equivalent rate of overall survival, disease-free survival and local and regional cancer control as compared to traditional WBI with boost after breast conserving surgery for selected patients with stage 0-II breast cancer. At five-year follow-up, cumulative recurrence rates for WBI and APBI were 1.44% and 0.92% (p=0.42) respectively. Five-year overall survival was 95.55% with WBI versus 97.27% for APBI and a low incidence of all serious late side effects (around 3% in both arms) was noted.

                              The new data presented provide additional insights into the late side effect and cosmetic results. Among the 1,184 original study patients, five-year follow-up records on late toxicities and cosmetic results were available for 969 patients (82%). The five-year toxicity profile was similar for patients treated with breast conserving surgery followed by either APBI using interstitial multicatheter brachytherapy or conventional WBI with tumor bed boost. However, a trend towards fewer late skin side effects and better cosmetic results was observed in the APBI arm.

                              There were no grade 4 toxicities reported. The cumulative incidence of grade 2-3 late skin toxicity at five years was 5.7% with WBI vs 3.2% with APBI (p=0.08). The cumulative risk of grade 2-3 late subcutaneous tissue effects at 5 years was 6.3% with WBI vs 7.6% with APBI (p=0.53). The cumulative incidence of severe (grade 3) fibrosis at five years was 0.2% with WBI and 0% with APBI (p=0.46). The cumulative incidence of grade 2-3 breast pain was low in both the WBI and APBI arms (3.2% vs 1.4%;p=0.04). The rate of excellent/good cosmetic results judged by patients was 87.2% with WBI vs 90.4% with APBI ,and 86.7% with  WBI vs 88.2% with APBI (p=0.07) when scored by physicians. However, significantly more patients (43.6% vs 30.9%; p=00002) experienced excellent cosmetic results after APBI.

                              “APBI with interstitial multicatheter brachytherapy offers a significantly shorter treatment course with equivalent local tumor control, less late skin side effects, and better cosmetic results compared to conventional WBI,” concludes Prof. Polgár.

                              “Early stage breast cancer has high unmet medical needs and places an enormous physical, emotional and economic burden on women, families and health care systems,” notes Prof. Vratislav Strnad, MD, PhD, chair of the GEC-ESTRO Breast Cancer Working Group and radiation oncologist at the Department of Radiation Oncology of University Hospital in Erlangen, Germany. “We anticipate these data will drive significant changes in how clinicians approach early stage breast cancer treatment in patients 50 years and older and place APBI multicatheter brachytherapy as an accepted standard alternative to whole breast irradiation.”

                              About APBI with Brachytherapy

                              Accelerated partial breast irradiation with brachytherapy (APBI brachytherapy) is a shortened course of high-dose radiation therapy for early-stage breast cancer patients where radiation is delivered directly into the tumor bed. APBI brachytherapy is delivered as part of breast conservation therapy (BCT), which consists of lumpectomy surgery followed by radiation.

                              The traditional approach for radiation therapy as part of BCT has been whole breast irradiation (WBI). A full course of WBI exposes the entire breast and surrounding critical structures to radiation and requires daily treatments for three to seven weeks where radiation is delivered from outside the breast. APBI brachytherapy delivers radiation only to the lumpectomy cavity and immediate surrounding tissue. APBI brachytherapy offers three significant advantages over WBI: a reduction in total radiation exposure, particularly to the heart, lungs and skin, a reduced treatment time and the preservation of future organ sparing treatment options. 

                              # # #

                              For further information, please contact:
                              Gert van Santen, Group Vice President Corporate Communications, Elekta AB
                              Tel: +31 653 561 242, Email: gert.vansanten@elekta.com
                              Time zone: CET: Central European Time
                               
                              Raven Canzeri, Global Public Relations Manager
                              Tel: +1 770 670 2524, Email: raven.canzeri@elekta.com
                              Time zone: EST: Eastern Standard Time
                               
                              About Elekta
                              Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

                              Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com Twitter: @Elekta.

                              • Products
                                • Radiation Therapy
                                • Stereotactic Radiosurgery
                                • Oncology Informatics
                                • Brachytherapy
                                • Neurosurgery
                                • Veterinary Radiation Therapy
                              • Services
                                • Elekta Care Customer Services
                                • Elekta Care Learning
                                • Elekta Care Community
                              • Patients
                                • Brachytherapy Treatment
                                • Gamma Knife Treatment
                                • Radiation Therapy Treatment
                                • Treatment Centers
                              • Company
                                • About us
                                • Sustainability
                                • Corporate Governance
                                • Investors
                                • Newsroom
                                • Careers at Elekta
                                • Country and regional pages
                                • Digital Product Security
                                • Offices
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube
                              • ©2022 Elekta
                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                              Contact and Support

                              Offices Customer support

                              By clicking the 'Submit' button below you agree to the Elekta Privacy Policy.

                              © 2022 Elekta

                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.